ArticleNature2025
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.Human vaccines & immunotherapeutics · 2026Pooled it
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials.International urology and nephrology · 2026Pooled it
- Mapping research trends in macrophage polarization and immunotherapeutic potential in prostate cancer: a bibliometric and visual analysis.Frontiers in oncology · 2026Pooled it
- Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- IL-1α Expands SLC2A1highSPP1highIFNlow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Precancers.Cancer research · 2026Article
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming.Cancer metastasis reviews · 2026Review
- Article
- UTMD Suppresses CSF-1 to Drive Macrophage-Mediated Ferroptosis in Papillary Thyroid Carcinoma.Cancer medicine · 2026Article
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Heterogeneous SPP1-expressing esophageal cancer cells license immunotherapy resistance by organizing an immunosuppressive niche.Neoplasia (New York, N.Y.) · 2026Article
- Context-dependent roles of osteopontin in aging-related neurological disorders.The Journal of international medical research · 2026Review
- Article
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.Nature communications · 2026Article
- Evolution of SPP1Cell reports. Medicine · 2026Article
- A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.Cancer research · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Aram Lyu *Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3044-4887
Zenghua Fan *Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Matthew ClarkDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Averey LeaDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Diamond LuongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Ali SetayeshDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Alec StarzinskiDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Rachel WoltersDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Marcel Arias-BadiaDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2270-0676
Kate AllaireDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Kai WuDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Vibha GurunathanDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Laura ValderrábanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xiao X WeiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Richard A MillerCorvus Pharmaceuticals, Burlingame, CA, USA.ORCID 0000-0002-5696-2503
Eliezer M Van AllenParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0000-0002-0201-4444
Lawrence FongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. lawrence.fong@fredhutch.org.ORCID 0000-0002-6428-428X
Funding
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAISSE, CHRISTIAN · 2003 to 2019
$21.8MDeterminants of response to cancer immunotherapyR35CA253175 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2021 to 2026
$5.8MMolecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2MBD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573kNCI NIH HHS R35 CA253175NCI NIH HHS U01 CA233100NIDDK NIH HHS P30 DK063720NIH HHS S10 OD021822
Abstract
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)
Indexed as
Drug Resistance, NeoplasmImmunotherapyMyeloid CellsProstatic Neoplasms, Castration-ResistantTumor-Associated MacrophagesAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesDisease Models, AnimalDisease ProgressionHumansImmune Checkpoint InhibitorsMaleMiceOsteopontinReceptors, Granulocyte-Macrophage Colony-Stimulating FactorB7-H1 AntigenImmune Checkpoint InhibitorsOsteopontinReceptors, Granulocyte-Macrophage Colony-Stimulating Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.